<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Acute and chronic heart failure with reduced ejection fraction (HFrEF) is a major public health problem, studies showing a 25% survival rate at 5 years after hospitalization. If left untreated, it is a common and potentially fatal disease. In recent years, the medical and device therapies of patients with HFrEF have significantly improved. The aim of our review is to provide an evidence-based update on new therapeutic strategies in acute and chronic settings, to prevent hospitalization and death in patients with HFrEF. We performed a systematic literature search on PubMed, EMBASE, and the Cochrane Database of Systemic Reviews, and we included a number of 23 randomized controlled trials published in the last 30 years. The benefit of beta-blockers and renin-angiotensin-aldosterone system inhibitors in patients with HFrEF is well known. Recent developments, such as sodium-glucose cotransporter 2 inhibitors, vericiguat, transcatheter mitral valve repair, wireless pulmonary artery pressure monitor and cardiac contractility modulation, have also proven effective in improving prognosis. In addition, other new therapeutic agents showed encouraging results, but they are currently being studied. The implementation of personalized disease management programs that directly target the cause of HFrEF is crucial in order to improve prognosis and quality of life for these patients.</p>
</abstract>

Acute and chronic heart failure with reduced ejection fraction (HFrEF) is a major public health problem, studies showing a 25% survival rate at 5 years after hospitalization. If left untreated, it is a common and potentially fatal disease. In recent years, the medical and device therapies of patients with HFrEF have significantly improved. The aim of our review is to provide an evidence-based update on new therapeutic strategies in acute and chronic settings, to prevent hospitalization and death in patients with HFrEF. We performed a systematic literature search on PubMed, EMBASE, and the Cochrane Database of Systemic Reviews, and we included a number of 23 randomized controlled trials published in the last 30 years. The benefit of beta-blockers and renin-angiotensin-aldosterone system inhibitors in patients with HFrEF is well known. Recent developments, such as sodium-glucose cotransporter 2 inhibitors, vericiguat, transcatheter mitral valve repair, wireless pulmonary artery pressure monitor and cardiac contractility modulation, have also proven effective in improving prognosis. In addition, other new therapeutic agents showed encouraging results, but they are currently being studied. The implementation of personalized disease management programs that directly target the cause of HFrEF is crucial in order to improve prognosis and quality of life for these patients.

New Perspectives in the Treatment of Acute and Chronic Heart Failure with Reduced Ejection Fraction

“Prof. Dr. George I.M. Georgescu” Cardiovascular Diseases Institute

“Grigore T. Popa” University of Medicine and Pharmacy

Journal of Cardiovascular Emergencies

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Acute and chronic heart failure with reduced ejection fraction (HFrEF) is a major public health problem, studies showing a 25% survival rate at 5 years after...

New Perspectives in the Treatment of Acute and Chronic Heart Failure with Reduced Ejection Fraction

Article Category: REVIEW

Publié en ligne: 30 déc. 2021

Pages: 88 - 99

Reçu: 05 avr. 2021

Accepté: 05 juil. 2021

DOI: https://doi.org/10.2478/jce-2021-0017

Mots clés
heart failure with reduced ejection fraction, drug treatment, device treatment, acute management, chronic management, quality of life

© 2021 Cristian Stătescu., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

New Perspectives in the Treatment of Acute and Chronic Heart Failure with Reduced Ejection Fraction

Article Category: REVIEW

Publié en ligne: 30 déc. 2021

Pages: 88 - 99

Reçu: 05 avr. 2021

Accepté: 05 juil. 2021

DOI: https://doi.org/10.2478/jce-2021-0017

Mots clésheart failure with reduced ejection fraction, drug treatment, device treatment, acute management, chronic management, quality of life

© 2021 Cristian Stătescu., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
heart failure with reduced ejection fraction, drug treatment, device treatment, acute management, chronic management, quality of life